Indian sentenced to 20 years jail term over Uzbekistan cough syrup deaths

The Supreme Court of Uzbekistan found Singh Raghvendra Pratap guilty of charges, including tax fraud and forgery, following a six-month long trial in the matter

India cough syrup, new drug policy
A total of 86 children in Uzbekistan suffered poisoning due to the syrup between 2022 and 2023, of which 68 died. (Representative Image)
Nisha Anand New Delhi
2 min read Last Updated : Feb 27 2024 | 4:00 PM IST
Uzbekistan sentenced an Indian national to a 20-year jail term on Monday for his role in the death of 68 children stemming from the intake of contaminated cough syrups in the nation. Singh Raghvendra Pratap and 20 other people linked to the case were handed out various sentences by the country.

Singh is the director of a company that imported the Doc-1 Max syrup into Uzbekistan. A total of 86 children in Uzbekistan suffered poisoning due to the syrup between 2022 and 2023, of which 68 died.

The Supreme Court of Uzbekistan found Singh guilty of charges, including tax fraud and forgery, following a six-month-long trial in the matter.

Toxic substances found in syrups 

According to the World Health Organisation's probe conducted on samples, toxic substances - diethylene glycol or ethylene glycol - were discovered in the syrups, which led to dozens of deaths.

Noida-based pharmaceutical firm Marion Biotech, responsible for the contaminated syrup production, had faced licence suspension over the issue in December 2022.

In January 2023, the WHO had labelled Marion's cough syrups as "substandard" and issued a medical product alert against its two items.

Haryana-based company also involved in controversy

Notably, before the Marion controversy, Haryana-based Maiden Pharmaceuticals was linked to the deaths of 70 children in Gambia due to the intake of contaminated cough syrup.

In February 2023, Maiden Pharma founder Naresh Kumar Goel and technical director M K Sharma were sentenced to jail by a Haryana court for exporting substandard drugs to Vietnam a decade ago. The company was banned in Vietnam in 2014 for quality-related violations.

India's pharma exports touched $24.5 billion in the financial year 2021-2022 (FY22).

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :UzbekistanCough syrupcentral governmentWorld Health OrganizationBS Web ReportsPharma Companies

First Published: Feb 27 2024 | 4:00 PM IST

Next Story